MedTrace Logo

A Clinical Study Investigating Rifampicin and Dolutegravir in Combination in Healthy Volunteers

NCT03199690 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2017-10-23

No results posted yet for this study

Summary

The purpose of the study is to see how the drug Dolutegravir is broken down by your body, when taken with another drug called Rifampicin. Dolutegravir is given to people as a treatment for HIV. Rifampicin is given to people as a treatment for tuberculosis.

Conditions

Interventions

DRUG

Dolutegravir

Antiviral (integrase inhibitor)

DRUG

Rifampicin

Antibiotic

Sponsors & Collaborators

  • St. Stephens Clinical Research

    lead OTHER

Study Design

Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-31
Primary Completion
2018-03-31
Completion
2018-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03199690 on ClinicalTrials.gov